Your browser is no longer supported. Please, upgrade your browser.
Settings
ABBV AbbVie Inc. daily Stock Chart
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E21.71 EPS (ttm)3.62 Insider Own0.10% Shs Outstand1.49B Perf Week-2.92%
Market Cap116.89B Forward P/E8.35 EPS next Y9.43 Insider Trans-15.84% Shs Float1.48B Perf Month-1.38%
Income5.74B PEG2.26 EPS next Q2.06 Inst Own71.90% Short Float1.55% Perf Quarter-11.28%
Sales32.75B P/S3.57 EPS this Y4.80% Inst Trans-0.05% Short Ratio3.51 Perf Half Y-12.50%
Book/sh-5.70 P/B- EPS next Y8.49% ROA8.80% Target Price92.18 Perf Year-15.05%
Cash/sh5.42 P/C14.50 EPS next 5Y9.59% ROE-202.20% 52W Range75.77 - 107.25 Perf YTD-14.68%
Dividend4.28 P/FCF16.21 EPS past 5Y7.60% ROI21.80% 52W High-26.48% Beta1.14
Dividend %5.44% Quick Ratio0.90 Sales past 5Y11.80% Gross Margin76.90% 52W Low4.06% ATR1.63
Employees30000 Current Ratio1.00 Sales Q/Q7.30% Oper. Margin19.50% RSI (14)41.55 Volatility2.27% 1.90%
OptionableYes Debt/Eq- EPS Q/Q-516.50% Profit Margin17.30% Rel Volume0.80 Prev Close78.66
ShortableYes LT Debt/Eq- EarningsApr 25 BMO Payout100.30% Avg Volume6.51M Price78.85
Recom2.80 SMA20-2.66% SMA50-1.75% SMA200-10.00% Volume3,756,161 Change0.24%
Mar-25-19Downgrade Argus Buy → Hold
Jan-23-19Initiated UBS Neutral $91
Jan-03-19Downgrade BofA/Merrill Buy → Neutral
Dec-26-18Initiated Standpoint Research Buy
Oct-22-18Reiterated SunTrust Buy $157 → $135
Oct-04-18Reiterated BofA/Merrill Buy $107 → $106
Jun-01-18Downgrade Piper Jaffray Overweight → Neutral
May-30-18Downgrade Credit Suisse Neutral → Underperform
Jan-30-18Reiterated Morgan Stanley Equal-Weight $99 → $131
Jan-29-18Downgrade Leerink Partners Outperform → Mkt Perform
Oct-30-17Reiterated Leerink Partners Outperform $108 → $107
Oct-02-17Upgrade Leerink Partners Mkt Perform → Outperform
Sep-25-17Downgrade UBS Buy → Neutral $79 → $92
Aug-17-17Initiated Evercore ISI Outperform $95
Jun-22-17Upgrade Societe Generale Hold → Buy
Mar-22-17Upgrade Societe Generale Sell → Hold
Oct-31-16Downgrade Credit Suisse Outperform → Neutral
Oct-18-16Initiated Leerink Partners Mkt Perform $70
Sep-08-16Downgrade JP Morgan Overweight → Neutral
Sep-02-16Initiated Raymond James Outperform $82
Apr-24-19 11:40AM  Biogen (BIIB) Beats on Q1 Earnings, Spinraza Drives Sales Zacks
11:31AM  Why Earnings Season Could Be Great for AbbVie (ABBV) Zacks
10:24AM  You can find plenty of solid stock bargains in this years worst-performing sector, analysts say MarketWatch
08:09AM  The Daily Biotech Pulse: FDA Greenlights AbbVie's Psoriasis Drug, Novartis Earnings, Patent Notification For MediciNova Benzinga
Apr-23-19 07:31PM  AbbVie's Skyrizi drug to treat psoriasis wins U.S. approval Reuters
06:37PM  AbbVie stock ticks higher on FDA approval of psoriasis treatment MarketWatch
06:19PM  AbbVie Expands Immunology Portfolio in the U.S. with FDA Approval of SKYRIZI (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis PR Newswire
Apr-22-19 05:00PM  Better Buy: Biogen vs. AbbVie Motley Fool
10:33AM  Is a Beat in Store for AbbVie (ABBV) This Earnings Season? Zacks
10:17AM  Biogen (BIIB) to Report Q1 Earnings: What's in the Cards? Zacks
08:15AM  AbbVie Reports Its Q1 Results on Thursday: Here's What You Can Expect Motley Fool
Apr-20-19 08:00AM  3 Cancer Treatment Stocks to Buy in April Motley Fool
Apr-19-19 02:12PM  5 Top Pharmaceutical Stocks to Buy in 2019 Motley Fool
12:19PM  5 Top Biotech Stocks to Buy in 2019 Motley Fool
Apr-18-19 10:59AM  Can Q1 Earnings Lift Healthcare ETFs Higher? Zacks
10:33AM  AbbVie (ABBV) Earnings Expected to Grow: Should You Buy? Zacks
10:22AM  Here Are the Key Takeaways From J&J's Q1 Earnings Report Zacks
10:04AM  Health Canada Approves SKYRIZI (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis CNW Group
Apr-17-19 09:30AM  AbbVie Falls 3% Investing.com
Apr-16-19 09:28PM  Is TG Therapeutics a Buy? Motley Fool
01:12PM  Top Marijuana Stocks That Pay Dividends Investopedia
10:58AM  J&J (JNJ) Beats on Q1 Earnings, Ups 2019 Sales Growth View Zacks
07:33AM  Is AbbVie Stock An Undiscovered Cannabis Play Waiting For Some Attention? InvestorPlace
Apr-15-19 05:45PM  AbbVie (ABBV) Gains As Market Dips: What You Should Know Zacks
07:09AM  8 Dividend Rich Blue Chips to Prosper as Buyback Mania Fades Investopedia
06:58AM  Goldman Sachs's 20 best stocks to invest in now Yahoo Finance
Apr-14-19 09:00AM  The Simple Way You Could Make 10% Each Year With AbbVie Motley Fool
Apr-12-19 02:02PM  Looking for a job? Here's the 2018 median pay at 50 top U.S. companies American City Business Journals
09:20AM  Forward Guidance Will Make or Break JNJ Earnings InvestorPlace
06:45AM  Do CEOs really make 100 times more than employees? They do at these big U.S. companies American City Business Journals
Apr-11-19 09:00AM  AbbVie's MAVIRET now reimbursed in Quebec CNW Group
Apr-10-19 03:24PM  Here's what to expect from the stock market next month Investopedia
10:20AM  J&J (JNJ) to Kick-start Pharma Q1 Earnings: What's in Store? Zacks
Apr-08-19 05:45PM  AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know Zacks
10:08AM  J&J Stock on an Uptrend This Year So Far: More Room to Run? Zacks
Apr-07-19 06:25PM  Better Buy: AbbVie vs. Johnson & Johnson Motley Fool
Apr-05-19 05:08PM  AbbVie: High-Yield Dividend Aristocrat Offering a No-Fee DRIP GuruFocus.com
03:37PM  Top Stock Reports for Boeing, Lockheed Martin & Anthem Zacks
Apr-04-19 01:17PM  10 Medical Marijuana Stocks to Cure Your Portfolio InvestorPlace
10:00AM  AbbVie Announces New Formulary Listings for its Hepatitis C Treatment MAVIRET CNW Group
09:39AM  Novartis Resubmits BLA to FDA for Biosimilar of Neulasta Zacks
Apr-03-19 09:58AM  Alector (ALEC) Initiates Phase I Alzheimer's Study on AL003 Zacks
08:00AM  AbbVie to Host First-Quarter 2019 Earnings Conference Call PR Newswire
Apr-02-19 10:21AM  Trump delays health care vote until after 2020 election Yahoo Finance Video
08:21AM  AbbVie Rises 3% Investing.com
Apr-01-19 05:45PM  AbbVie (ABBV) Gains But Lags Market: What You Should Know Zacks
04:30PM  Alector Initiates Phase 1 Trial of AL003 for the Treatment of Patients with Alzheimers Disease GlobeNewswire
Mar-31-19 07:03AM  Better Buy: AbbVie vs. Johnson & Johnson Motley Fool
Mar-30-19 12:39PM  3 High-Yield Stocks at Rock-Bottom Prices Motley Fool
Mar-29-19 05:24PM  Can These Biotech Stocks Take On Arthritis Powerhouse AbbVie? Investor's Business Daily
03:23PM  Wall Street is buzzing about Gileads rheumatoid arthritis drug. Heres why MarketWatch
12:45PM  Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates Benzinga
12:12PM  Can These Biotech Stocks Take On Arthritis Powerhouse AbbVie? Investor's Business Daily
Mar-28-19 05:44PM  AbbVie's big acquisition blowup: A one-off or an omen? American City Business Journals
10:00AM  Drug giant cutting 178 jobs, three years after buying Peninsula biotech for $6 billion American City Business Journals
Mar-27-19 09:26PM  Real Estate Deals of the Year: AbbVie lease American City Business Journals
05:49PM  How this cancer-fighting startup switched gears, landed a big deal and started a clinical trial American City Business Journals
Mar-26-19 11:18AM  AbbVie's Psoriasis Drug Skyrizi Gets First Approval in Japan Zacks
09:06AM  Were Hedge Funds Right About AbbVie Inc (ABBV)? Insider Monkey
07:36AM  The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs Benzinga
01:00AM  AbbVie Announces First Regulatory Approval of SKYRIZI (risankizumab) for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis and Psoriatic Arthritis in Japan PR Newswire
Mar-25-19 05:45PM  AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know Zacks
Mar-24-19 06:33PM  4 Blockbuster Drug Launches to Watch in 2019 Motley Fool
02:00PM  3 Bargain Stocks You Can Buy Today Motley Fool
09:07AM  Where Will AbbVie Be in 10 Years? Motley Fool
Mar-22-19 09:15AM  This is Why AbbVie (ABBV) is a Great Dividend Stock Zacks
Mar-21-19 08:00PM  Better Buy: AbbVie vs. Eli Lilly Motley Fool
07:56AM  Does Recent Weakness in AbbVie Stock Make It a Buy? 3 Pros, 3 Cons InvestorPlace
Mar-20-19 11:10AM  AbbVie's Venclexta Multiple Myeloma Studies Put on Hold by FDA Zacks
Mar-19-19 10:21AM  Why You Should Buy ABBV Stock for Income and Value InvestorPlace
09:36AM  FDA puts partial hold on clinical trials of AbbVie's cancer drug Reuters
09:07AM  AbbVie stock down 0.8% after FDA places hold on clinical trials of venetoclax as a treatment for multiple myeloma MarketWatch
09:01AM  FDA puts partial hold on clinical trials of AbbVie's cancer drug Reuters
08:45AM  AbbVie Provides Update on VENCLEXTA®/VENCLYXTO® (venetoclax) Multiple Myeloma Program PR Newswire
Mar-18-19 05:45PM  AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know Zacks
01:36PM  Big Pharma Earnings Might Not Be as Good as They Look Barrons.com
Mar-17-19 09:03AM  2 Things Investors Are Missing About AbbVie Motley Fool
Mar-14-19 10:36AM  Roche Receives EC Approval for Label Expansion of Hemlibra Zacks
09:14AM  3 Dividend Aristocrats to Buy and Hold Forever Motley Fool
06:00AM  The Timely Ten- Blue Chip Buys with Value and Yield MoneyShow
05:01AM  Blue Chip Drug Stocks Face 'Reckoning' on Future Downgrades Investopedia
Mar-13-19 02:27PM  Theravance (TBPH) Starts Dosing in Ulcerative Colitis Study Zacks
08:37AM  FDA medical adviser: 'Congress is owned by pharma' Yahoo Finance
Mar-12-19 05:07PM  Takeda's Entyvio Tops AbbVie's Humira in Patients With Ulcerative Colitis GuruFocus.com
10:50AM  Pfizer's Herceptin Biosimilar Trazimera Gets FDA Approval Zacks
Mar-11-19 05:45PM  AbbVie (ABBV) Gains But Lags Market: What You Should Know Zacks
11:05AM  Should Value Investors Consider Abbvie (ABBV) Stock Now? Zacks
Mar-10-19 10:36AM  10 Stocks For The Gene Therapy Revolution Investopedia
09:00AM  4 Stocks to Buy With Dividends Yielding More Than 4% Motley Fool
Mar-08-19 01:45PM  Pharma Stock Roundup: FDA OK's J&J Antidepressant, CHMP Recommends Several Drugs Zacks
10:20AM  Dont Abandon Gilead Stock After Weak Q4 Results InvestorPlace
09:35AM  Roche's (RHHBY) Tecentriq Gets EC Nod for First-Line NSCLC Zacks
Mar-07-19 03:32PM  The Kiplinger Dividend 15 Is On a Roll Kiplinger
10:35AM  UPDATE: Bio-Path stock gains another 130% on Thursday MarketWatch
08:46AM  AbbVie Announces Multiple Milestones for Phase 3 CLL14 Venetoclax Study of Fixed Duration Treatment in Previously-Untreated Chronic Lymphocytic Leukemia Patients PR Newswire
08:40AM  Vertex's VX-445 Triple Combo Cystic Fibrosis Trials Succeed Zacks
06:03AM  2 Biotech Stocks With Major Incoming Catalysts Motley Fool
Mar-06-19 01:32PM  7 Stocks That Can Outperform In a Post QE Market Investopedia
09:15AM  Are You Looking for a High-Growth Dividend Stock? AbbVie (ABBV) Could Be a Great Choice Zacks
Mar-05-19 09:51AM  The Zacks Analyst Blog Highlights: Intel, AbbVie, United Technologies, Simon Property and FirstEnergy Zacks
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; and Calico Life Sciences LLC. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Durkin Brian LVP, ControllerMar 25Sale79.6947537,8539,121Mar 25 04:34 PM
Schumacher Laura JVice ChairmanMar 14Sale80.0025,0002,000,000139,838Mar 15 05:53 PM
SALEKI-GERHARDT AZITAEVP, OperationsMar 05Sale79.0315,7971,248,48093,312Mar 06 05:03 PM
Schumacher Laura JVice ChairmanDec 28Sale90.0025,0002,250,000134,322Jan 02 04:49 PM
CHASE WILLIAM JEVP, Finance & AdministrationDec 12Sale90.0060,0005,400,000104,863Dec 14 05:12 PM
GONZALEZ RICHARD AChairman of the Board and CEODec 11Sale88.7516,8501,495,438286,203Dec 13 04:56 PM
Schumacher Laura JExecutive Vice PresidentDec 04Option Exercise51.4294,1404,840,679192,398Dec 07 05:15 PM
Schumacher Laura JExecutive Vice PresidentDec 04Sale93.5894,1408,809,55298,258Dec 07 05:15 PM
Gosebruch Henry OEVP, Chief Strategy OfficerNov 29Sale90.1042,4503,824,94030,350Nov 30 05:22 PM
SEVERINO MICHAELEVP, R&D and CSOAug 17Sale97.5250,0004,876,06082,281Aug 21 04:58 PM
TILTON GLENN FDirectorJun 27Buy91.905,400496,27439,735Jun 29 02:30 PM
RAPP EDWARD JDirectorJun 20Buy98.631,01399,90920,743Jun 22 05:56 PM